Skip to content

Effect of potassium competitive acid blockers on upper gastrointestinal mucosal flora in patients with non-erosive gastroesophageal reflux disease

Effect of potassium competitive acid blockers on upper gastrointestinal mucosal flora in patients with non-erosive gastroesophageal reflux disease

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066936
Enrollment
Unknown
Registered
2022-12-21
Start date
2022-12-22
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-erosive gastroesophageal reflux disease

Interventions

The group of NERD :potassium competitive acid blockers
Control group:None

Sponsors

Suining Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1 ) Age = 45 years, < 60 years ; 2 ) Compliance with NERD diagnostic criteria : a. Have symptoms of acid reflux and/or heartburn; b. Gastroscopy was negative; c. 24h esophageal PH-impedance monitoring showed excessive acid and alkali reflux in the esophagus; 3) No achalasia or other primary or secondary esophageal motility disorders; 4) No hiatal hernia, peptic ulcer, atrophic gastritis, liver cirrhosis; 5) No Hp infection or other serious infectious diseases; 6) No digestive system malignancy or other system malignancy; 7) History of supreme gastrointestinal surgery; 8) No history of chronic diseases such as diabetes, thyroid dysfunction or immune system related diseases; 9) Patients who have not used antibiotics or probiotics in the past three months; 10) He has not used proton pump inhibitors, H2 receptor antagonists or gastrointestinal motility agents in the past two months; 11) No severe cardiopulmonary insufficiency; 12) Female patients who are not currently pregnant or breastfeeding; 13) No history of mental illness, genetic or metabolic disease; 14) Voluntarily accept and abide by the study protocol, tolerate related examinations, complete the questionnaire independently under the guidance of the investigator, and accept the review and clinical follow-up on time.

Exclusion criteria

Exclusion criteria: 1 ) Age < 45 or = 60 ; 2)Confirmed diagnosis of cardia retardation or other primary and secondary esophageal motility disorders; 3) No hiatal hernia, peptic ulcer, atrophic gastritis, liver cirrhosis; 4) Patients with Hp infection or other serious infectious diseases; 5) Definite diagnosis of digestive system malignancy or other system malignancy in the past or present; 6) History of upper gastrointestinal surgery; 7) A history of chronic diseases such as diabetes, thyroid dysfunction or immune system related diseases; 8) Patients who have used antibiotics or probiotics in the past 3 months; 9) Have used proton pump inhibitors, H2 receptor antagonists and gastrointestinal motility drugs, and stopped using them for less than 2 months; 10) Patients with severe cardiopulmonary insufficiency or other diseases may not tolerate the examination; 11) Pregnant or lactating women; 12) History of mental illness, genetic or metabolic disease; 13) Patients who are not willing to participate in this study.

Design outcomes

Primary

MeasureTime frame
flora;

Countries

China

Contacts

Public ContactHe Suyu

No. 127 Desheng Road West, Chuanshan District, Suining, Sichuan

hesuyu2009@163.com+86 18008258565

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026